Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

This report provides the real-world safety and effectiveness of sacituzumab govitecan, which was recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). Data from patients who had received sacituzumab govitecan as treatment for mTNBC, in both de novo and relapsed disease, were collected through institutional records and analyzed for safety parameters and survival outcomes and reported using descriptive statistics.